Cumulus cloud

Cumulus Media Announces Expanded Partnership With Rich Eisen

Retrieved on: 
Wednesday, September 6, 2023
Cumulus Media, NFL, Football, EuroLeague MVP of the Round, Human, Westwood, Monday Night Football, Guglielmo Marconi, Female, Westwood One, CMLS, Fan, Name, Humour, Sport, Hysterical, Rich Eisen, Cumulus cloud, Emmy Awards, Retail

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced a new deal with Emmy- and Marconi-nominated host Rich Eisen for the Cumulus Podcast Network to distribute, market, and monetize all existing and forthcoming podcasts with the newly formed Rich Eisen Podcast Network.

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cumulus Media (NASDAQ: CMLS) today announced a new deal with Emmy- and Marconi-nominated host Rich Eisen for the Cumulus Podcast Network to distribute, market, and monetize all existing and forthcoming podcasts with the newly formed Rich Eisen Podcast Network.
  • Most recently, Eisen launched Overreaction Monday on September 4th to make for a big week in football from the growing Rich Eisen Podcast Network.
  • Eisen also anchors his flagship podcast, The Rich Eisen Show , which blends sports, pop culture, humor, and interviews, discussing topical issues not commonly addressed by sportscasters.
  • “Since joining the Cumulus family, they have shown unwavering support for my vision in growing my brand,” said Eisen.

Cloudelligent and CoreStack Partner to Deliver Cloud-Native Expertise and Optimize AWS Infrastructures

Retrieved on: 
Tuesday, August 1, 2023
Software, Technology, Artificial Intelligence, Data Management, Cloud, Well, Alfred Wells (architect), Partnership, Agility, Secop, NPO “Digital Television Systems”, DnB NORD, FTR, Luigi, Ecosystem, Micro ISV, AWS, Sales, Risk management, Compass, Cumulus cloud

Cloudelligent, an AWS Advanced Consulting Partner, and CoreStack, a global multi-cloud governance provider, announced today a technology partnership that will equip businesses with NextGen Cloud Governance to mitigate risk, accelerate delivery, optimize performance, and innovate faster.

Key Points: 
  • Cloudelligent, an AWS Advanced Consulting Partner, and CoreStack, a global multi-cloud governance provider, announced today a technology partnership that will equip businesses with NextGen Cloud Governance to mitigate risk, accelerate delivery, optimize performance, and innovate faster.
  • CoreStack’s AI driven multi-cloud governance platform provides continuous and autonomous governance through Compass and Cumulus product lines.
  • These solutions streamline evaluating, improving, and maintaining cloud workloads across all environments, including enabling auto-remediation directly from the CoreStack dashboard.
  • Cloudelligent is one of the fastest-growing partners in the AWS ecosystem and brings deep expertise in AWS.

Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Retrieved on: 
Monday, July 17, 2023
Communication, University, Clinic, Sleep, Data collection, Bristol Myers Squibb, Boston University, Biomarker, Language, CNS, Wakefulness, Trial of the century, Amel Association International, Doctor of Philosophy, Dementia, MD, Patient, Collection, EEG, Amnesia, Confusion, Neurology, Personality, Boston University Chobanian & Avedisian School of Medicine, AD, Health, Function (mathematics), Memory, Conference, Behavior, Medical imaging, Medical device, Alzheimer's disease, Medicine, Cumulus cloud

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.

Key Points: 
  • BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
  • Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
  • Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
  • Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.

Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Retrieved on: 
Monday, July 17, 2023
Communication, University, Clinic, Sleep, Data collection, Bristol Myers Squibb, Boston University, Biomarker, Language, CNS, Wakefulness, Trial of the century, Amel Association International, Doctor of Philosophy, Dementia, MD, Patient, Collection, EEG, Amnesia, Confusion, Neurology, Personality, Boston University Chobanian & Avedisian School of Medicine, AD, Health, Function (mathematics), Memory, Conference, Behavior, Medical imaging, Medical device, Alzheimer's disease, Medicine, Cumulus cloud

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.

Key Points: 
  • BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 17, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented interim data from their real-world feasibility study CNS-101 at the Alzheimer's Association International Conference 2023 in Amsterdam, Netherlands.
  • Purely digital markers are scalable but lack objectivity," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus.
  • Importantly, the remote data captured in this study was of similar quality to data generated using traditional methods in house at Boston University."
  • Dr. Budson and his team receive funding and other resources from Bristol Myers Squibb and Cumulus Neuroscience.

Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets

Retrieved on: 
Monday, July 17, 2023
Lead, Therapy, Cancer, Computational chemistry, Neoplasm, GPCR, Machine learning, VCS, Drug discovery, Membrane, Nursing, Medical imaging, Pharmaceutical industry, G protein-coupled receptor, Cumulus cloud

leadXpro will use its structural biology expertise, combining proprietary technology in protein structure determination, coupled with biophysical characterisation and computational modelling, to generate novel compounds.

Key Points: 
  • leadXpro will use its structural biology expertise, combining proprietary technology in protein structure determination, coupled with biophysical characterisation and computational modelling, to generate novel compounds.
  • Cumulus Oncology brings a team of successful life science entrepreneurs with deep oncology sector knowledge and a recognised track record in translational oncology drug development.
  • A GPCR portfolio company, created by Cumulus Oncology, focused on novel GPCR targets on tumours and the tumour microenvironment, will have the option to license the Lead compound series as well as resulting intellectual property from the research collaboration.
  • The founding team at Cumulus consists of successful life science entrepreneurs, scientists and a range of oncology drug development and pharma sector business professionals.

Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer's Dementia

Retrieved on: 
Thursday, July 13, 2023
Communication, University Hospitals Bristol and Weston NHS Foundation Trust, University, Psychology, Pathology, Innovation, Research, Biomarker, Language, CNS, North Bristol NHS Trust, Behavior, Associate, Doctor of Philosophy, UKCA, Fastball, Patient, Physician, EEG, NIHR, Amnesia, Neurology, Confusion, Diagnosis, Personality, NHS, AD, FDA, Health, Oscillation, Memory, Caregiver, Disease, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Alzheimer's disease, Dementia, Bristol, Cumulus cloud

Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.

Key Points: 
  • Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
  • Importantly, as a passive test, performance is not impacted by anxiety level, education level or language.
  • They have also demonstrated that this response changes when a person develops dementia, offering hope for its potential as a breakthrough for earlier diagnosis.
  • We are honored to partner with the Universities of Bath and Bristol on this important study."

Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer's Dementia

Retrieved on: 
Thursday, July 13, 2023
Communication, University Hospitals Bristol and Weston NHS Foundation Trust, University, Psychology, Pathology, Innovation, Research, Biomarker, Language, CNS, North Bristol NHS Trust, Behavior, Associate, Doctor of Philosophy, UKCA, Fastball, Patient, Physician, EEG, NIHR, Amnesia, Neurology, Confusion, Diagnosis, Personality, NHS, AD, FDA, Health, Oscillation, Memory, Caregiver, Disease, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Alzheimer's disease, Dementia, Bristol, Cumulus cloud

Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.

Key Points: 
  • Dr. Liz Coulthard , Associate Professor in Dementia Neurology at the University of Bristol and neurologist at North Bristol National Health Service (NHS) Trust , is the project co-lead.
  • Importantly, as a passive test, performance is not impacted by anxiety level, education level or language.
  • They have also demonstrated that this response changes when a person develops dementia, offering hope for its potential as a breakthrough for earlier diagnosis.
  • We are honored to partner with the Universities of Bath and Bristol on this important study."

Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Retrieved on: 
Wednesday, July 12, 2023
Cognition, Frontotemporal dementia, Trinity College, Science Foundation Ireland, Neurodegenerative disease, Spinal cord, European Network for Health Technology Assessment, Academic Unit Preparatoria Hermanos Flores Magón, Brain, Research, Language, CNS, Brain cell, Doctor of Philosophy, Fatigue, Trinity College Dublin, Frasier, Behavior, Patient, EEG, Deficit spending, ECAS, Health, FTD, Function (mathematics), Memory, Caregiver, White coat hypertension, Disease, Regulation, Nursing, Medical imaging, Neurology, Cumulus cloud, ALS

The study also demonstrated that digital remote measurements can be used to stratify healthy subjects and patients, providing positive evidence for task validity and technical feasibility.

Key Points: 
  • The study also demonstrated that digital remote measurements can be used to stratify healthy subjects and patients, providing positive evidence for task validity and technical feasibility.
  • We are deeply grateful to the patients, caregivers and collaborators who dedicated their time to this important first-in-class study."
  • Key behavioral and EEG endpoints were evaluated cross-sectionally based on data from the first five sessions for each assessment.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Retrieved on: 
Wednesday, July 12, 2023
Cognition, Frontotemporal dementia, Trinity College, Science Foundation Ireland, Neurodegenerative disease, Spinal cord, European Network for Health Technology Assessment, Academic Unit Preparatoria Hermanos Flores Magón, Brain, Research, Language, CNS, Brain cell, Doctor of Philosophy, Fatigue, Trinity College Dublin, Frasier, Behavior, Patient, EEG, Deficit spending, ECAS, Health, FTD, Function (mathematics), Memory, Caregiver, White coat hypertension, Disease, Regulation, Nursing, Medical imaging, Neurology, Cumulus cloud, ALS

The study also demonstrated that digital remote measurements can be used to stratify healthy subjects and patients, providing positive evidence for task validity and technical feasibility.

Key Points: 
  • The study also demonstrated that digital remote measurements can be used to stratify healthy subjects and patients, providing positive evidence for task validity and technical feasibility.
  • We are deeply grateful to the patients, caregivers and collaborators who dedicated their time to this important first-in-class study."
  • Key behavioral and EEG endpoints were evaluated cross-sectionally based on data from the first five sessions for each assessment.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Cumulus Media Announces Final Results of Tender Offer

Retrieved on: 
Wednesday, June 14, 2023
Transfer, CMLS, Cumulus cloud, BofA Securities, Security (finance)

ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ: CMLS) (the "Company” or "Cumulus") today announced the final results of its "modified Dutch auction" tender offer, which expired at midnight, New York City time, at the end of the day on June 9, 2023.

Key Points: 
  • ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Cumulus Media Inc. (NASDAQ: CMLS) (the "Company” or "Cumulus") today announced the final results of its "modified Dutch auction" tender offer, which expired at midnight, New York City time, at the end of the day on June 9, 2023.
  • Based on the final count by Continental Stock Transfer & Trust Company, the depositary for the tender offer, in accordance with the terms and conditions of the tender offer, the Company has accepted for payment a total of 1,745,005 shares of the Company’s Class A common stock, at a final purchase price of $3.25 per share, for an aggregate cost of approximately $5.7 million, excluding fees and expenses relating to the tender offer.
  • These shares represent approximately 9.8% of the Company’s outstanding Class A common stock as of June 13, 2023.
  • BofA Securities, Inc. acted as the dealer manager for the tender offer and D.F.